RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

• ClinicalTrials.gov Identifier: NCT00193856
• Recruitment Status: Completed
• First Posted: September 19, 2005
• Last Update Posted: October 12, 2017
• Sponsor: Trans Tasman Radiation Oncology Group
• Collaborators: National Health and Medical Research Council, Australia; Hunter Medical Research Institute (HMRI); Health Research Council, New Zealand; Novartis Pharmaceuticals; Cancer Society of New Zealand; University of Newcastle, Australia; Calvary Mater Newcastle, Australia; Maitland Cancer Appeal; Abbott
• Information provided by (Responsible Party): Trans Tasman Radiation Oncology Group

Study Description

Brief Summary:

The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2) that 18 months Bisphosphonate therapy will prevent bone loss caused by androgen deprivation therapy and further reduce relapse risk by impeding the development of bony metastases.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Drug: Leuprorelin Acetate; Drug: Zoledronic Acid; Radiation: Conventional external beam therapy	Phase 3

Detailed Description:

Traditionally androgen deprivation (by orchidectomy, or more recently by medication) has been reserved for the palliative treatment of men with advanced, incurable prostate cancer. However, evidence from large scale trials is beginning to suggest that androgen deprivation (AD) may be helpful in preventing relapse in patients with more localised disease who are treated surgically or by radiotherapy. Of the 8000 patients per annum who are treated with curative intent, one half (4000) have cancers where 'adjuvant' AD may be prescribed according to interpretation of the registered indications. There are, however, enormous variations in prescribing practices which reflect uncertainty as to the appropriate indications. An important issue is osteopenia.

The increasing use of AD in men with earlier stages of cancer, whose life expectancies exceed 3 years, has exposed many unwanted metabolic sequelae of prolonged AD, the most important being osteopenia. In 1996, with the funding support of the NHMRC and the pharmaceutical industry, TROG therefore launched a large randomised three-arm trial. Two of the arms repeated the two arms of the US Radiation Therapy Oncology Group (RTOG) 86.01 trial which, at the time, was showing early indications of benefit for the addition of two months maximal androgen deprivation (MAD), using Goserelin (Zoladex) and Flutamide, before radiation therapy and one month during. Since work from Canada had indicated that continued AD for periods longer than three months produced additional shrinkage of the prostatic tumour, the TROG 96.01 trial incorporated a third arm: six months MAD prior to and during radiotherapy. The trial completed its recruitment target of 800 eligible patients in early 2000. Although in August 2001 the median follow up time was still very short, a preliminary analysis indicated that significant increases in time to biochemical relapse had been produced by AD. In fact, the benefits of AD were independent of stage, tumour grade and initial PSA value which were confirmed also to predict time to biochemical failure. The hazard of relapse reduced to 0.75 (0.55 - 0.97, 95% confidence intervals) with 3 months AD, and still further to 0.6 (0.45 - 0.82) with six months AD.

Subsequent international developments in this area of research encouraged the design of a 'follow on' trial. A European Organisation for Research and Treatment of Cancer (EORTC) trial reported that 3 years of adjuvant ('post hoc') AD (using Goserelin alone), administered after radiotherapy, reduced relapse and improved survival in patients with locally advanced prostate cancer. The US Radiation Therapy Oncology Group (RTOG) 85.31 trial indicated that indefinite Goserelin administration after radiotherapy reduced treatment failure rates at all sites when compared with radiotherapy alone. The RTOG 92.02 trial showed that 24 months of adjuvant Goserelin also reduced failure rates in patients treated with 4 months of MAD prior to and during radiotherapy. Subset analyses of the RTOG trials, suggested that patients who gain most from prolonged AD in terms of survival are those with high grade cancers.

It was therefore logical for TROG to propose a second trial with the intention of finding out whether an additional 12 months of AD administered after radiotherapy (aka 'intermediate term' AD [ITAD]) would reduce relapse and mortality in patients treated with six months of AD prior to and during radiotherapy (aka 'short term' AD [STAD]) as in the 'best' arm of its first (96.01) trial. The availability of the potent bisphosphonate, zoledronic acid, also made it possible to find out whether or not osteopenia induced in the two arms of the proposed second trial would be prevented by a second random assignment to 18 months' bisphosphonate therapy (BP).

This is a randomised phase III multicentre clinical trial.

After informed consent is given and eligibility is checked patients will be randomised to one of four trial arms:

1. 6 months of androgen blockade with an LH-RH analogue (5 months before start of radiotherapy) (STAD),
2. 18 months of androgen blockade with an LH-RH analogue (starting 5 months before start of radiotherapy) (ITAD),
3. 18 months of therapy with zoledronic acid 4 mg by intravenous infusion every 3 months for 18 months beginning concurrently with STAD
4. 18 months of therapy with zoledronic acid beginning concurrently with ITAD.

Stratification will be according to the following criteria:

T2 / T3, 4 Gleason score 2 - 6 / 7+ Presenting PSA <10 / 10 - 20 / >20 Treatment centre

Radiation Treatment will be delivered using a conventional technique, unless the treatment centre of the participating clinician demonstrates an ability to deliver the treatment using a CRT, IMRT, or HDRB technique verified by the trial TACT.

Drug Treatment:

LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an Intramuscular injection (IMI).

Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to this therapy. No placebo therapy will be given to patients randomised to 'no bisphosphonate therapy' treatment arm.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1071 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate.
• Study Start Date: October 2003
• Actual Primary Completion Date: August 2017
• Actual Study Completion Date: August 2017

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: A; LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)	Drug: Leuprorelin Acetate; LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).; Radiation: Conventional external beam therapy; The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Active Comparator: B; LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.	Drug: Leuprorelin Acetate; LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).; Drug: Zoledronic Acid; Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.; Radiation: Conventional external beam therapy; The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Experimental: C; LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)	Drug: Leuprorelin Acetate; LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).; Radiation: Conventional external beam therapy; The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Experimental: D; LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.	Drug: Leuprorelin Acetate; LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).; Drug: Zoledronic Acid; Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.; Radiation: Conventional external beam therapy; The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.

Outcome Measures

Primary Outcome Measures :

1. Prostate cancer-specific mortality. [ Time Frame: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant ]

Secondary Outcome Measures :

1. Cumulative incidence of PSA progression [ Time Frame: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant ]
2. Cumulative incidence of local, distant and bony progression and associated patterns of clinical progression [ Time Frame: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant ]
3. All-cause mortality [ Time Frame: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant ]
4. Changes in bone mineral density and osteopenic fracture [ Time Frame: One endpoint analysis is planned when 4.5 years have elapsed from randomisation of the last participant ]
5. Quality of life assessment [ Time Frame: One endpoint analysis is planned when 3 years have elapsed from randomisation of the last participant ]
6. Treatment related morbidity [ Time Frame: One endpoint analysis is planned when 4 years have elapsed from randomisation of the last participant ]
7. Cumulative incidence of secondary therapeutic intervention [ Time Frame: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomization of the last participant ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histological confirmation of adenocarcinoma of the prostate in the three months prior to randomisation
• Gleason primary and secondary pattern reported. If the volume of tumour in biopsies is too small for the pathologist to allocate a secondary pattern, the primary pattern alone is sufficient.
• Primary tumour stage T2b - 4 (UICC 2002), or T2a providing biopsies demonstrate Gleason score 7 or more, and presenting PSA 10 or more
• PSA value obtained within one month of randomisation
• No evidence of lymphatic or haematogenous metastases, as determined by negative chest x-ray, CT scan of abdomen and pelvis, and bone scan in the 3 months prior to randomisation
• ECOG performance status 0 - 1
• No concurrent medical conditions likely to significantly reduce prospects of 5 year survival
• Patient accessible to follow up at intervals specified in protocol
• Written informed consent given (signed by both patient and investigator prior to randomisation)

Exclusion Criteria:

• Previous or concurrent malignancy within previous 5 years except for non-melanomatous skin cancer
• Prostatectomy
• Prior pelvic radiotherapy
• Prior hormone treatment for prostate cancer
• Inability to complete self administered QOL questionnaire
• Prior bisphosphonate therapy
• Serum creatinine > 2 x ULN
• Osteoporosis resulting in >30% loss in vertebral height in one or more thoraco-lumbar vertebrae
• Liver disease resulting in ALT or AST levels >3 x ULN
• Prolonged continuous glucocorticoid therapy > 10 mg/day of prednisone equivalent (>6 months)
• Current treatment with bisphosphonate
• Inability to attend for follow-up at the Investigator's clinic

Contacts and Locations

Locations

Australia, New South Wales

Campbelltown Hospital

Campbelltown, New South Wales, Australia, 2560

St George Hospital

Kogarah, New South Wales, Australia, 2217

Lismore Hospital

Lismore, New South Wales, Australia, 2480

Liverpool Hospital

Liverpool, New South Wales, Australia, 1871

Calvary Mater Newcastle

Newcastle, New South Wales, Australia, 2298

Nepean Cancer Care Centre

Penrith, New South Wales, Australia, 2751

Royal North Shore Hospital

Sydney, New South Wales, Australia, 2069

Riverina Cancer Care Centre

Wagga Wagga, New South Wales, Australia, 2650

Westmead Hospital

Wentworthville, New South Wales, Australia, 2145

Illawarra Cancer Care Centre

Wollongong, New South Wales, Australia

Australia, Queensland

Royal Brisbane Hospital

Herston, Queensland, Australia, 4029

Mater QRI

South Brisbane, Queensland, Australia, 4101

John Flynn Private Hospital

Tugun, Queensland, Australia, 4224

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia, 4102

Australia, Tasmania

Launceston General Hospital

Launceston, Tasmania, Australia, 7250

Australia, Victoria

Peter MacCallum Cancer Centre

East Melbourne, Victoria, Australia, 8006

Andrew Love Cancer Care Centre, Geelong Hospital

Geelong, Victoria, Australia, 3220

Australia, Western Australia

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia, 6009

New Zealand

Auckland Hospital

Auckland, New Zealand, 1001

Christchurch Hospital

Christchurch, New Zealand, 4710

Dunedin Hospital

Dunedin, New Zealand

Waikato Hospital

Hamilton, New Zealand, 3200

Palmerston North Hospital

Palmerston North, New Zealand

Wellington Hospital

Wellington, New Zealand, 7902

Sponsors and Collaborators

Trans Tasman Radiation Oncology Group

National Health and Medical Research Council, Australia

Hunter Medical Research Institute (HMRI)

Health Research Council, New Zealand

Novartis Pharmaceuticals

Cancer Society of New Zealand

University of Newcastle, Australia

Calvary Mater Newcastle, Australia

Maitland Cancer Appeal

Abbott

Investigators

• Study Chair: Jim Denham, FRANZCR; University of Newcastle, Australia

More Information

Additional Information:

Click here for more information about this study on the TROG official website 

Publications of Results:

Haworth A, Kearvell R, Greer PB, Hooton B, Denham JW, Lamb D, Duchesne G, Murray J, Joseph D. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study. Radiother Oncol. 2009 Mar;90(3):299-306. doi: 10.1016/j.radonc.2008.10.011. Epub 2008 Nov 18.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.

Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, Denham JW, Ebert MA. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol. 2016 Oct 31;11(1):144. doi: 10.1186/s13014-016-0719-2.

Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday EG, Attia J. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol. 2015 Jun;115(3):301-7. doi: 10.1016/j.radonc.2015.05.016. Epub 2015 Jun 10.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12. Erratum In: Lancet Oncol. 2014 Sep;15(10):e417. Dosage error in article text.

Denham JW, Wilcox C, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Ebert M, Delahunt B, McElduff P, Joseph D. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiother Oncol. 2012 Nov;105(2):184-92. doi: 10.1016/j.radonc.2012.09.018. Epub 2012 Nov 3.

• Responsible Party: Trans Tasman Radiation Oncology Group
• ClinicalTrials.gov Identifier: NCT00193856
• Other Study ID Numbers: TROG 03.04; ACTRN12607000097448 ( Registry Identifier: Australian New Zealand Clinical Trials Registry )
• First Posted: September 19, 2005
• Last Update Posted: October 12, 2017
• Last Verified: October 2017

Keywords provided by Trans Tasman Radiation Oncology Group:

Prostate Cancer; Androgen Deprivation; Hormone Therapy; RadiotherapyBisphosphonate; Prostate Specific Antigen (PSA)

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Zoledronic Acid; Leuprolide; Bone Density Conservation Agents; Physiological Effects of Drugs; Fertility Agents, Female; Fertility Agents; Reproductive Control Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents